Skin Condition
Conditions
Brief summary
To assess the efficacy of Pitaya Ovule Extract on skin
Interventions
DIETARY_SUPPLEMENTPlacebo drink
consume 1 bottle per day
DIETARY_SUPPLEMENTPitaya Ovule Extract Drink
consume 1 bottle per day
Sponsors
TCI Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* 20 to 65-year-old males or females
Exclusion criteria
* Received medical cosmetic treatment (including cosmetic skin care, laser, fruit acid peeling, injection or plastic surgery, etc.) currently or within one month before the trial * Outdoor workers (exposed to the sun more than 5 hours a day) * People who are breastfeeding, pregnant or planning to become pregnant during the test (self-report) * People with heart, liver, kidney, endocrine and other major organic diseases (self-reported) * People who have undergone major surgery (according to medical history) * People who take drugs for a long time * People with mental illness * Students who are currently taking courses taught by the principal investigator of this trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The change of Matrix metalloproteinases (MMP-2, MMP-9) of blood | Change from Baseline MMPs at 8 weeks | Venous blood was sampled to measure MMPs |
| The change of skin texture | Change from Baseline skin texture at 8 weeks | IRV skin analyzer was utilized to measure skin texture. Units: arbitrary units |
| The change of skin pores | Change from Baseline skin pores at 8 weeks | IRV skin analyzer was utilized to measure skin pores. Units: arbitrary units |
| The change of skin tone | Change from Baseline skin tone at 8 weeks | IRV skin analyzer was utilized to measure skin tone. Units: arbitrary units |
| The change of Advanced glycation end products of blood | Change from Baseline AGEs at 8 weeks | Venous blood was sampled to measure AGEs |
| The change of RAGE (receptor for advanced glycation end products) of blood | Change from Baseline RAGE at 8 weeks | Venous blood was sampled to measure RAGE |
| The change of L* (lightness) values | Change from Baseline L* value at 8 weeks | Spectrophotometer SCM-108 was utilized to measure skin L\* value. Units: arbitrary units |
| The change of skin elasticity | Change from Baseline skin elasticity at 8 weeks | Cutometer® Dual MPA580 was utilized to measure skin elasticity. Units: arbitrary units |
| The change of skin collagen density | Change from Baseline skin collagen density at 8 weeks | DermaLab® Combo Ultrasound module was utilized to measure skin collagen density. Units: arbitrary units |
| The change of skin wrinkles | Change from Baseline skin wrinkles at 8 weeks | IRV skin analyzer was utilized to measure skin wrinkles. Units: arbitrary units |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The change of renal function biomarkers (creatinine, BUN) of blood | Change from Baseline renal function biomarkers at 8 weeks | Venous blood was sampled to measure renal function biomarkers |
| The change of fasting blood glucose level | Change from Baseline fasting blood glucose level at 8 weeks | Venous blood was sampled to measure fasting blood glucose level |
| Change from Baseline insulin level at 8 weeks | Change from Baseline insulin level at 8 weeks | Venous blood was sampled to measure insulin level |
| The change of blood lipid profile | Change from Baseline blood lipid profile at 8 weeks | Venous blood was sampled to measure blood lipid profile (total cholesterol, HDL-C, LDL-C, triglyceride) |
| The change of liver function biomarkers (AST, ALT) of blood | Change from Baseline liver function biomarkers at 8 weeks | Venous blood was sampled to measure liver function biomarkers |
Countries
Taiwan
Outcome results
None listed